Data are presented as n or n/N total (%), unless otherwise stated. ^#: Multivariable logistic regression analysis adjusted for sex, race, age at diagnosis, healthcare insurance status, use of steroids, multiorgan involvement and other sarcoidosis-related comorbidities (cancer, chronic pain syndrome, congestive heart failure and lymphoma). The effective sample size that was kept in the adjusted complete-case analyses was 92% for depression, 81% for “feeling depressed”, 90% for antidepressants use, 92% for obesity, 87% for sleep apnoea, 92% for chronic fatigue syndrome, 82% for “feeling tired”, 92% for fibromyalgia, 92% for “use of mobility device”, 90% for disability, 51% for work days missing and 67% for job termination. ^¶: Depression disorder developed after the diagnosis of sarcoidosis as reported by respondents. ⁺: Feeling depressed or feeling tired defined if patient answered feeling tired/depressed often or always. ^§: Antidepressants reported include citalopram (Celexa), fluoxetine (Prozac), escitalopram (Lexapro), fluvoxamine (Luvox), duloxetine (Cymbalta), venlafaxine (Effexor), paroxetine (Paxil) and sertraline (Zoloft). ^ƒ: Mobility assistive devices include canes, scooters, walkers and wheelchairs.